Roche Presents P-III Studies (COMMODORE 1 & 2) Results of Crovalimab for the Treatment of Paroxysmal Nocturnal Haemoglobinuria at EHA 2023
Shots:
- The P-III studies evaluating crovalimab (SC, q4w) vs eculizumab (IV, q2w) in a ratio (1:1) & (2:1) in 89 & 204 patients. In the (COMMODORE 2) study, 79.3% vs 79.0% achieved haemolysis control from 5wk. to 25wk., transfusion avoidance (65.7% vs 68.1%) from baseline to 25wk.
- Improvement in FACIT-fatigue score from baseline to 25wk. across both arms with greater improvement with crovalimab (adjusted mean change 7.8 vs 5.2), AEs (78% vs 80%), serious inf. (3% vs 7%) with no meningococcal inf., 1 patient experienced an AE leading to treatment discontinuation
- The (COMMODORE 1) study results showed maintained disease control in patients switching from currently approved complement inhibitors. Both studies' results will be submitted to regulatory authorities globally
Ref: Globenewswire | Image: Roche
Related News:- Genentech Reports P-III Study (COMMODORE 2) Results of Crovalimab for Paroxysmal Nocturnal Hemoglobinuria
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
